[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Janot F, Julieron M: [Functional surgery for head and neck squamous cell carcinoma]. Bull Cancer; 2002 Dec;89(12):1011-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional surgery for head and neck squamous cell carcinoma].
  • [Transliterated title] Chirurgie conservatrice des cancers des voies aérodigestives supérieures.
  • Surgery for head and neck squamous cell carcinoma can alter speech, swallowing, and cosmoses.
  • Recent tendency is to avoid mutilating surgery unless the tumour is aggressive or resistant to chemotherapy and or radiotherapy.
  • Functional surgery is being widely employed, and for example it may vary between conventional partial surgery and endoscopic laser surgery for small sized vocal cord cancers.
  • Various new reconstructive procedures have been developed to help early functional restoration.
  • Few recently developed techniques can be also employed in selected cases of laryngo-pharyngeal cancers to avoid permanent laryngeal mutilation.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Glossectomy. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Laryngectomy. Laryngoscopy. Mandible / surgery. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / radiotherapy. Pharyngeal Neoplasms / surgery. Pharyngectomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525359.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Arya AK, El-Fert A, Devling T, Eccles RM, Aslam MA, Rubbi CP, Vlatković N, Fenwick J, Lloyd BH, Sibson DR, Jones TM, Boyd MT: Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer; 2010 Jul 13;103(2):186-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
  • BACKGROUND: Primary radiotherapy (RT) is a mainstay of treatment for laryngeal squamous cell carcinoma (LSCC).
  • Although the cure rates for early (T1) vocal cord tumours are high, RT proves ineffective in up to a third of T3 carcinomas.
  • Moreover, RT is associated with debilitating early- and late-treatment-related toxicity, thus finding means to de-escalate therapy, while retaining/augmenting therapeutic effectiveness, is highly desirable. p53 is a key mediator of radiation responses; we therefore investigated whether Nutlin-3, a small-molecule inhibitor of MDM2 (mouse double minute 2; an essential negative regulator of p53), might radiosensitise LSCC cells.
  • RESULTS: LSCC cells harbouring wild-type p53 were significantly radiosensitised by Nutlin-3 (P<0.0001; log-rank scale), and displayed increased cell cycle arrest and significantly increased senescence (P<0.001) in the absence of increased apoptosis; thus, our data suggest that senescence may mediate this increased radiosensitivity.
  • CONCLUSION: This is the first study showing Nutlin-3 as an effective radiosensitiser in LSCC cells that retain wild-type p53.
  • The clinical application of Nutlin-3 might improve local recurrence rates or allow treatment de-escalation in these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cell Aging / drug effects. Genes, p53. Imidazoles / analysis. Imidazoles / pharmacology. Laryngeal Neoplasms / drug therapy. Piperazines / analysis. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Animals. Cell Proliferation / drug effects. Cell Survival / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):303-5 [12726854.001]
  • [Cites] Science. 1996 Nov 8;274(5289):948-53 [8875929.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):824-7 [9041179.001]
  • [Cites] Cytometry. 1998 Jan 1;31(1):1-9 [9450519.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2154-61 [10070281.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2455-63 [10499619.001]
  • [Cites] Cell Cycle. 2004 Jul;3(7):900-4 [15254433.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):545-53 [15632057.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1918-24 [15753391.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Surgeon. 2005 Jun;3(3):197-205 [16076005.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3150-9 [16014563.001]
  • [Cites] Cell Cycle. 2006 Jan;5(1):39-42 [16322696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):411-7 [16505116.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):183-92 [16697662.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):909-23 [17128209.001]
  • [Cites] J Cell Sci. 2006 Dec 15;119(Pt 24):5015-20 [17158908.001]
  • [Cites] Cell Cycle. 2007 Mar 1;6(5):595-605 [17351335.001]
  • [Cites] Methods Mol Biol. 2007;371:21-31 [17634571.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7350-7 [17671205.001]
  • [Cites] Anticancer Drugs. 2007 Oct;18(9):1053-68 [17704656.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):355-66 [17936560.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9862-8 [17942917.001]
  • [Cites] N Engl J Med. 2007 Dec 20;357(25):2552-61 [18094376.001]
  • [Cites] PLoS One. 2008;3(9):e3230 [18800172.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):993-1000 [14707282.001]
  • [Cites] Mol Cancer Res. 2003 Dec;1(14):1017-26 [14707285.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 [15234026.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):419-21 [15004525.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] Arch Otolaryngol. 1981 Nov;107(11):703-10 [7295166.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Oct;91(5):482-91 [6417595.001]
  • [Cites] Br J Radiol. 1985 Jun;58(690):515-28 [4063711.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] Radiat Environ Biophys. 1995 Jun;34(2):79-83 [7652155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):574-87 [20142252.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):385-94 [10637254.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1813-23 [11747320.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):117-29 [12563311.001]
  • [Cites] Otolaryngol Clin North Am. 2002 Oct;35(5):993-1012 [12587244.001]
  • [Cites] Cell Death Differ. 2003 Apr;10(4):431-42 [12719720.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5187-90 [7585571.001]
  • (PMID = 20588277.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 8313
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Piperazines; 0 / Radiation-Sensitizing Agents; 53IA0V845C / nutlin 3; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2906734
  •  go-up   go-down


3. Pradeep PV, Agarwal A, Baxi M, Agarwal G, Gupta SK, Mishra SK: Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country. World J Surg; 2007 Feb;31(2):306-12; discussion 313
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though surgical management of toxic multinodular goiter (MNG) is well accepted, surgical treatment of Graves' disease (GD) is still controversial in view of the presumed increased incidence of complications.
  • The indications for surgery in Graves' patients were large goiter, relapse after antithyroid drug therapy (ATD), Graves' ophthalmopathy, and presence of nodule.
  • Hemithyroidectomy was the procedure of choice in patients with AFTN.
  • Eight percent of patients with Graves' disease without a clinically palpable nodule and 25% of those with nodules had associated differentiated carcinoma, including papillary, follicular, and medullary thyroid cancer.
  • Complications included temporary hypocalcemia (24%), permanent hypocalcemia (3%), and permanent vocal-cord palsy (1%).
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. India. Male. Middle Aged. Patient Satisfaction. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1999 Nov;178(5):377-80 [10612531.001]
  • [Cites] Thyroid. 1998 Apr;8(4):277-82 [9588491.001]
  • [Cites] ANZ J Surg. 2002 May;72(5):321-4 [12028087.001]
  • [Cites] Surg Today. 2004;34(12):997-1001 [15580380.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):833-47 [15145238.001]
  • [Cites] Eur J Endocrinol. 1995 Apr;132(4):406-12 [7711876.001]
  • [Cites] Br J Surg. 1993 Sep;80(9):1134-6 [8402112.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):849-74 [15145239.001]
  • [Cites] Am J Surg. 2006 Mar;191(3):400-5 [16490555.001]
  • [Cites] N Engl J Med. 2005 Mar 3;352(9):905-17 [15745981.001]
  • [Cites] Endocr Rev. 2000 Apr;21(2):168-99 [10782363.001]
  • [Cites] Am Fam Physician. 2005 Aug 15;72(4):623-30 [16127951.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1733-8 [1489388.001]
  • [Cites] Thyroid. 1998 Aug;8(8):647-52 [9737358.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1111-3 [10931060.001]
  • [Cites] Eur J Surg. 1997 Sep;163(9):651-7 [9311471.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):299-314 [2436323.001]
  • [Cites] J Indian Med Assoc. 2001 May;99(5):252, 254-6 [11676109.001]
  • [Cites] J Assoc Physicians India. 1995 Sep;43(9):600-1 [8773059.001]
  • [Cites] J Postgrad Med. 2001 Oct-Dec;47(4):244-7 [11832639.001]
  • [Cites] Thyroid. 2005 Jun;15(6):569-74 [16029123.001]
  • [Cites] BMJ. 1992 Sep 26;305(6856):727-8 [1422325.001]
  • [Cites] World J Surg. 2001 Mar;25(3):307-10 [11343181.001]
  • (PMID = 17219271.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Laccourreye O, Veivers D, Bassot V, Ménard M, Brasnu D, Laccourreye H: Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure. Ann Otol Rhinol Laryngol; 2002 Apr;111(4):315-21; discussion 321-2
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with a platinum-based chemotherapy-alone regimen for cure.
  • Based on an inception cohort of 35 patients with T1-3N0M0 squamous cell carcinoma of the true vocal cord who had a complete clinical response after a platinum-based induction chemotherapy regimen and a minimum of 3 years of follow-up, the current retrospective study documented the long-term results and consequences of local recurrence following the use of a platinum-based chemotherapy-alone regimen for cure.
  • During the years 1985 to 1996, 231 patients with invasive squamous cell carcinoma of the true vocal cord classified as T1-3N0M0 were managed at our department with a platinum-based induction chemotherapy regimen.
  • Thirty-five of the 77 patients with complete clinical response were managed at our institution with a platinum-based chemotherapy-alone regimen.
  • Salvage treatment in patients with local recurrence yielded a 100% local control rate and laryngeal preservation rate.
  • Although local recurrence was noted in almost a third of patients with complete clinical response who were managed with a platinum-based chemotherapy-alone regimen, it did not appear to be detrimental, as none of the patients who had local recurrence ultimately died from their disease or lost their larynx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local. Vocal Cords
  • [MeSH-minor] Actuarial Analysis. Adult. Aged. Chi-Square Distribution. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2002 Sep;111(9):860 [12296346.001]
  • (PMID = 11991582.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Tomaszewski D, Zajac-Lenczewska I, Plichta L, Lapiński M, Murawski M, Sternau A, Skokowski J: [Effect of neoadjuvant chemotherapy on complications in patients undergoing surgical treatment for non small cell lung cancer]. Pneumonol Alergol Pol; 2004;72(11-12):477-81
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of neoadjuvant chemotherapy on complications in patients undergoing surgical treatment for non small cell lung cancer].
  • Neoadjuvant chemotherapy before resection is being the standard of care for stage IIIA non-small cell lung cancer in many institutions.
  • The risk of complications in patients undergoing thoracotomy after induction chemotherapy remain controversial.
  • From 1998 to 2003, 29 patients underwent pulmonary resection after induction chemotherapy for advanced non-small cell lung cancer.
  • The postoperative complications included pneumonia in 2 patients, postoperative bleeding in 2, hemothorax in 1, prolonged intubation in 1, vocal cord paralysis in 2, cardiac arrhythmia in 2, atelectasis in 1 and residual air space in 1, resulting in 41,4% morbidity.
  • The mortality of patients who had received induction chemotherapy was higher than that of a comparative group of 1529 who underwent lung resection or only exploration without induction chemotherapy during the same period, and the difference was significant (10.3% vs 4.1%; p = 0.01).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Neoadjuvant Therapy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Pneumonectomy / adverse effects. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16329346.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Iloabachie K, Nathan CO, Ampil F, Morgan ML, Caldito G: Return of vocal cord movement: an independent predictor of response to nonsurgical management of laryngeal cancers. Laryngoscope; 2007 Nov;117(11):1925-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Return of vocal cord movement: an independent predictor of response to nonsurgical management of laryngeal cancers.
  • OBJECTIVE: To determine whether return of vocal cord function after treatment of T2b/T3 laryngeal carcinoma is an independent prognostic factor for locoregional recurrence.
  • STUDY DESIGN: A retrospective review of patients treated with radiation +/- chemotherapy between 2000 and 2005 for T2 with vocal cord paresis and T3 laryngeal carcinoma was conducted.
  • Patients' charts were reviewed for local and regional recurrence after treatment.
  • Six patients had T2 lesions with vocal cord paresis, and eight patients had T3 lesions.
  • Fifty percent of patients with T2 and 75% of patients with T3 lesions had return of vocal cord function after treatment.
  • Five of 14 patients did not have return of vocal cord function, and of these, 100% had locoregional recurrence.
  • Of the nine patients who had return of vocal cord movement, none of the patients had recurrence.
  • The proportion of recurrence was significantly higher for those whose vocal function did not return compared with the patients whose vocal function returned (100% vs. 0%, P < .01).
  • CONCLUSION: The immobile vocal cord is associated with a worse prognosis and is therefore factored into the American Joint Commission on Cancer staging for laryngeal tumors.
  • We show that vocal cord immobility is an independent prognostic factor of recurrence even after treatment and can predict treatment failure in T2 and T3 lesions of the larynx.
  • [MeSH-major] Laryngeal Neoplasms / radiotherapy. Recovery of Function. Vocal Cord Paralysis / etiology
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Risk Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17828050.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Hinerman RW, Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB: T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience. Am J Clin Oncol; 2007 Apr;30(2):181-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution's 35-year experience.
  • PURPOSE: The purpose of this study was to report the outcomes after external-beam radiotherapy (RT) for selected T3 and T4 vocal cord squamous cell carcinomas.
  • METHODS AND MATERIALS: One hundred nine patients with previously untreated T3 and T4 squamous cell carcinomas of the glottic larynx were treated with curative intent in this Institutional Review Board-approved outcome study using continuous-course RT alone (106 patients) or followed by a planned neck dissection (3 patients) between September 1966 and June 2002.
  • Patients selected for such treatment had relatively low-volume, unilateral disease.
  • Patients were staged according to the recommendations of the American Joint Committee on Cancer (AJCC) as follows: T3N0, 68 patients (62%); T3N1, 14 patients (13%); T3N2B, 5 patients (5%); T4N0, 17 patients (16%); T4N1, 4 patients (4%); and T4N2B, 1 patient.
  • RESULTS: The 5-year outcomes after treatment were: local control for stage T3 and T4, 78% and 81%; locoregional control for AJCC stage III and IVa, 62% and 78%; distant metastasis-free survival for AJCC stage III and IVa, 97% and 100%; cause-specific survival for AJCC stage III and IVa, 84% and 87%; and overall survival for AJCC stage III and IVa, 52% and 67%, respectively.
  • CONCLUSIONS: The results of this retrospective study compare favorably with those published elsewhere in the literature for T3 and T4 vocal cord carcinomas.
  • Local control and ultimate cure probabilities will hopefully improve further with the addition of concomitant chemotherapy to RT for larger tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy. Vocal Cords
  • [MeSH-minor] Disease-Free Survival. Humans. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414468.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Pelizzo MR, Piotto A, Bergamasco A, Rubello D, Casara D: [Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience]. Minerva Endocrinol; 2001 Mar;26(1):23-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience].
  • [Transliterated title] Il carcinoma delle paratiroidi. Strategie terapeutiche derivate da 20 anni di esperienza.
  • BACKGROUND: Carcinoma of the parathyroid is a rare endocrine tumour which can be difficult to diagnose even for expert anatomopathologists.
  • METHODS: A retrospective study was carried out on all the cases of parathyroid pathology observed between January 1980 and October 2000: parathyroid carcinoma was diagnosed in 17 (3.59%) out of 478 patients treated for hyperparathyroidism.
  • We describe their clinical presentation, treatment and results obtained.
  • The patients included 9 women and 8 men, with a male/female ratio of 1.14 and a mean age at diagnosis of 56.9 years (range 30-83).
  • RESULTS: Parathyroid carcinoma was correctly diagnosed during the first operation in 14 cases (this diagnosis was suspected in 10 cases following intraoperative frozen session), whereas the first diagnosis was of benign disease in 3 patients.
  • Two patients underwent radiotherapy after surgery and one received chemotherapy.
  • [MeSH-major] Carcinoma / surgery. Parathyroid Neoplasms / surgery. Parathyroidectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Gastritis / etiology. Humans. Hypercalcemia / etiology. Hyperparathyroidism / etiology. Italy / epidemiology. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Osteoporosis / etiology. Reoperation. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Urinary Calculi / etiology. Vocal Cord Paralysis / etiology

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11323564.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 15
  •  go-up   go-down


9. Choi BS, Robins HI: Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine. Cancer Chemother Pharmacol; 2008 Feb;61(2):345-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
  • Described is the first reported case of paclitaxel-induced recurrent laryngeal nerve paralysis in a patient receiving adjuvant therapy for breast cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Vinblastine / analogs & derivatives. Vocal Cord Paralysis / chemically induced
  • [MeSH-minor] Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / drug therapy. Female. Humans. Laryngeal Nerves / physiopathology. Middle Aged. Neoplasm Metastasis. Neurotoxicity Syndromes / physiopathology. Peripheral Nervous System Diseases / chemically induced. Peripheral Nervous System Diseases / physiopathology. Recurrence

  • Genetic Alliance. consumer health - paralysis.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026678.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  •  go-up   go-down


10. Kapteijns EF, Kwakkel-van Erp JM, Vos PJ, van den Elshout FJ: [Dyspnoea caused by upper-airway obstruction: simple diagnosis by establishing a flow-volume loop]. Ned Tijdschr Geneeskd; 2006 May 6;150(18):993-8
MedlinePlus Health Information. consumer health - Choking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dyspnoea caused by upper-airway obstruction: simple diagnosis by establishing a flow-volume loop].
  • [Transliterated title] Dyspneu door vernauwing in de bovenste luchtwegen: eenvoudige diagnostiek met een flowvolumecurve.
  • The first patient had oesophageal carcinoma with vocal-cord paralysis and soon died.
  • The third patient was diagnosed with extragonadal testicular carcinoma.
  • The flow-volume loop improved after the first chemotherapy session.
  • [MeSH-major] Airway Obstruction / diagnosis. Dyspnea / diagnosis. Lung Volume Measurements / methods
  • [MeSH-minor] Adult. Aged. Carcinoma / complications. Esophageal Neoplasms / complications. Fatal Outcome. Humans. Male. Vocal Cord Paralysis / complications

  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715859.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Nur DA, Oguz C, Kemal ET, Ferhat E, Sülen S, Emel A, Münir K, Ann CS, Mehmet S: Prognostic factors in early glottic carcinoma implications for treatment. Tumori; 2005 Mar-Apr;91(2):182-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in early glottic carcinoma implications for treatment.
  • AIM: In this study we aimed to determine the prognostic factors affecting local control (LC) in limited glottic carcinoma treated with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Between June 1991 and December 2001, 114 patients with early squamous-cell carcinoma of the glottis were treated with definitive RT at our institution.
  • Prior to RT 35 (31%) patients had undergone vocal cord stripping and two (2%) cordectomy.
  • A median dose of 66 Gy (50-70.2) was given over a median period of 46 days (20-60).
  • The prognostic parameters analyzed for LC were T classification, anterior commissure involvement, total RT dose, and overall treatment time.
  • In 15 patients with local failure, salvage treatment consisted of partial laryngectomy in eight patients and total laryngectomy in five.
  • In one of the three patients with regional failure, salvage surgery was applied and the other two were given palliative chemotherapy because of unresectable disease.
  • Following salvage treatments, the ultimate five-year LC rate was 96.9% and the five-year larynx preservation rate was 91.1%.
  • Second primary cancer was diagnosed in 17 (14.9%) patients.
  • Only one patient developed distant metastases and two patients died of laryngeal cancer.
  • CONCLUSION: In patients with early glottic carcinoma, T classification proved to be the only independent prognostic factor affecting LC after primary radiotherapy according to the results of this study.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary. Prognosis. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948549.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rollins M, McKay WR, McKay RE: Airway difficulty after a brachial plexus subclavian perivascular block. Anesth Analg; 2003 Apr;96(4):1191-2, table of contents
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMPLICATIONS: We report a case of upper airway obstruction after subclavian perivascular block in a patient with a preexisting unrecognized paralyzed vocal cord on the opposite side.
  • We discuss the incidence of vocal cord paralysis after subclavian perivascular block and the risk of airway compromise if contralateral vocal cord paralysis is known or suspected.
  • [MeSH-major] Brachial Plexus. Nerve Block / adverse effects. Respiratory Tract Diseases / chemically induced. Vocal Cord Paralysis / chemically induced
  • [MeSH-minor] Aged. Anesthetics, Local / adverse effects. Bupivacaine / adverse effects. Carcinoma, Squamous Cell / surgery. Epinephrine / adverse effects. Female. Humans. Oxygen Inhalation Therapy. Respiratory Sounds / drug effects. Tongue Neoplasms / surgery. Vasoconstrictor Agents / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12651683.001).
  • [ISSN] 0003-2999
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Vasoconstrictor Agents; Y8335394RO / Bupivacaine; YKH834O4BH / Epinephrine
  •  go-up   go-down


13. Majid MA, Siddique MI: Major post-operative complications of thyroid surgery: preventable or not? Bangladesh Med Res Counc Bull; 2008 Dec;34(3):99-103
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent procedure was bilateral subtotal thyroidectomy.
  • Reactionary hemorrhage occurred in 6 patients, all following bilateral procedures and among them 5 patients developed tension hematoma with respiratory obstruction despite the presence of a drain.
  • Temporary vocal cord palsy was observed in 7 patients whereas one patient subjected to total thyroidectomy with neck dissection for papillary carcinoma of thyroid developed permanent right vocal cord palsy.
  • Temporary parathyroid insufficiency was seen in 51 patients and one patient developed permanent hypoparathyroidism.
  • There was no operation related death in this series, but complications like hemorrhage, vocal cord palsy and parathyroid insufficiency following thyroid surgery are still a deep concern.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Goiter, Nodular / surgery. Humans. Hypoparathyroidism / etiology. Male. Middle Aged. Postoperative Hemorrhage / etiology. Retrospective Studies. Vocal Cord Paralysis / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476256.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


14. Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Mancuso AA: Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck; 2003 Jul;25(7):535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck.
  • PURPOSE: To analyze parameters that may influence the likelihood of local control after definitive radiotherapy for head and neck cancer.
  • METHODS: Between April 1980 and January 2000, 404 patients were treated with definitive RT alone (358 patients) or combined with adjuvant chemotherapy (46 patients) at our institution and were followed up for 0.25 to 20.25 years (median, 3.5 years.
  • Parameters evaluated in multivariate analyses of these end points included primary site, T stage, primary tumor volume, N stage, histologic differentiation, fractionation schedule, adjuvant chemotherapy, and gender.
  • RESULTS: The rates of local control and local control without a severe late complication after RT were significantly influenced by primary tumor volume for patients with cancer of the supraglottic larynx and true vocal cord.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Predictive Value of Tests. Radiotherapy / adverse effects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley Periodicals, Inc. Head Neck 25: 535-542, 2003
  • (PMID = 12808656.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Pelaz AC, Rodrigo JP, Mancebo G, Suárez C: Anterior cervical abscess as a complication of CO2 laser surgery of the larynx. J Craniofac Surg; 2010 May;21(3):790-1
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior cervical abscess as a complication of CO2 laser surgery of the larynx.
  • We describe the case of a patient who had a big anterior cervical abscess 1 month after having undergone an endoscopic laser CO2 cordectomy to treat an epidermoid carcinoma of the left vocal cord.
  • Computed tomography scan revealed an extensive anterior cervical abscess.
  • As far as we are concerned, our present case is the first reporting this extremely rare complication, an anterior cervical abscess appearing 1 month after an endoscopic laser CO2 procedure.
  • [MeSH-major] Abscess / drug therapy. Abscess / etiology. Laryngectomy / adverse effects. Laser Therapy / adverse effects. Neck
  • [MeSH-minor] Aged. Carbon Dioxide. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Abscess.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485050.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


16. Agarwal A, Mishra SK: Role of surgery in the management of Graves' disease. J Indian Med Assoc; 2001 May;99(5):252, 254-6
Genetic Alliance. consumer health - Graves' Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for surgery included patients with large goitre, relapse after antithyroid drug (ATD) therapy, allergic reactions to ATD, non-compliance and finally an associated nodule with suspicion of carcinoma.
  • There was no case of permanent recurrent laryngeal nerve damage or hypoparathyroidism.
  • Eight patients (11.1%) had temporary unilateral vocal cord palsy and 4 patients (5.5%) had temporary hypocalcemia.
  • One patient (1.4%) developed recurrent hyperthyroidism.
  • Postoperative transient hypothyroidism developed in 87.5% cases, all within the first postoperative year.
  • The functional results at 2 years were as follows: Out of 47 cases followed 31 patients (65.9%) became euthyroid while 15 (31.9%) were still hypothyroid and requited long term substitutive treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11676109.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


17. Weymuller EA Jr: Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with platinum-based chemotherapy--alone regimen for cure. Ann Otol Rhinol Laryngol; 2002 Sep;111(9):860
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of local recurrence in patients with selected T1-3N0M0 squamous cell carcinoma of the true vocal cord managed with platinum-based chemotherapy--alone regimen for cure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell. Neoplasm Recurrence, Local. Vocal Cords

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Otol Rhinol Laryngol. 2002 Apr;111(4):315-21; discussion 321-2 [11991582.001]
  • (PMID = 12296346.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Chang CY, Martinu T, Witsell DL: Bilateral vocal cord paresis as a presenting sign of paraneoplastic syndrome: case report. Otolaryngol Head Neck Surg; 2004 Jun;130(6):788-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral vocal cord paresis as a presenting sign of paraneoplastic syndrome: case report.
  • [MeSH-major] Paraneoplastic Syndromes / diagnosis. Vocal Cord Paralysis / diagnosis
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / immunology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Humans. Laryngoscopy / methods. Lung Neoplasms / complications. Lung Neoplasms / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15195068.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down






Advertisement